Annual report [Section 13 and 15(d), not S-K Item 405]

Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details)

v3.25.1
Income Taxes - Schedule of Components of the Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Deferred tax assets:    
Net operating losses carry forward $ 47,875 $ 41,698
Deferred revenue 8,217 8,219
Share-based compensation 1,572 1,512
Research and development/orphan drug credits 23,296 20,509
Capitalized research and development expenses 20,664 18,684
Others (11) (57)
Less: valuation allowance (101,613) (90,565)
Deferred tax assets, net